RxDoctor Payments DataLook up a doctor →

Fahad Gilani, MD

Cardiovascular Disease · Manchester, NHNPI 1184884975

Payments from drug & device makers

$509,863in general payments, 2019–2025

Across 727 payments — averaging $701.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$385K
  • Abbott$85K
  • Edwards Lifesciences$33K
  • Cardinal Health 200 LLC$2K
  • Inari Medical, Inc.$1K
  • Shockwave Medical, Inc$654
  • plus $3K from 18 others

What the payments were for

  • Consulting fees$47,70011%
  • Speaking & faculty fees$300,61972%
  • Travel & lodging$50,61812%
  • Food & beverage$18,7374%
  • Other$2820%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$509,863 in reported general payments places this provider in the 95th percentile of 112 cardiovascular disease providers in New Hampshire.

See all cardiovascular disease providers in New Hampshire

Medicare billing

Part B allowed, 2024
$213,581
Medicare patients
544
Services billed
1,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban90$89,998
XareltoRivaroxaban16$23,039
JardianceEmpagliflozin11$11,208
Metoprolol Succinate190$2,006
Torsemide24$1,002
Rosuvastatin Calcium40$909
Potassium Chloride42$696
Atorvastatin Calcium79$624
Furosemide73$499
Losartan Potassium48$432
Lisinopril51$386
ClopidogrelClopidogrel Bisulfate28$319
Nitroglycerin16$231
Warfarin Sodium19$179
Isosorbide Mononitrate ErIsosorbide Mononitrate17$157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$86$89,99890 claims
Johnson & JohnsonXarelto$24$23,03916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 112 cardiovascular disease providers in New Hampshire.

Other cardiovascular disease in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →